FDA ad­comm to de­cide on mol­nupi­ravir EUA; Can­cer at­las un­veils new po­ten­tial drug tar­get

The FDA has an­oth­er ad­comm com­ing down the pipeline — this time on Covid-19 oral an­tivi­ral mol­nupi­ravir.

The fed­er­al agency’s ad­vi­so­ry com­mit­tee will meet on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER